Clinical trials: Systemic Lupus
System; Lupus Erythematosus
Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on…
- Trial name
- NCT04907175
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Systemic Lupus Erythematosus
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy and safety of IMC-002 and IMM0306S in the treatment of active SLE.
- Trial name
- NCT06535412
- Testing
- IMC-002 + SOC, IMM0306S + SOC
- Where
- China
- Volunteers
- 218 people
- Sponsor
- ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
System Lupus Erythematosus
Vagus Nerve Stimulation for Fatigue in Systemic Lupus
50female patients diagnosed with systemic lupus erythematosus according to the 2010 Revised American College of Rheumatology (ACR). Their age will range from 35 to 55 years.
- Trial name
- NCT07256067
- Testing
- transcutaneous vagus nerve stimulation (tVNS)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Cardiovascular Diseases, Coronary Disease
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
To study longitudinally the incidence, pathogenesis, and risk factors for thrombotic events and coronary artery disease in a cohort of patients with systemic lupus erythematosus (SLE).
- Conditions
- Cardiovascular Diseases, Coronary Disease, Thrombosis, Heart Diseases
- Trial name
- NCT00005436
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Lupus Erythematosus, Systemic
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms.
- Trial name
- OPUS-1 (NCT05648500)
- Testing
- Cenerimod
- Where
- 198 sites in United States, Argentina and 15 more
- Volunteers
- 470 people
- Sponsor
- Viatris Innovation GmbH
Systemic Lupus Erythematosus
Study of CM355 in Patients With Systemic Lupus Erythematosus
This study was designed to investigate the safety and efficacy of CM355 in patients with refractory SLE.
- Trial name
- NCT07104344
- Testing
- CM355
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Lupus Nephritis, Systemic Lupus Erythematosus
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).
- Trial name
- MISSION (NCT03393013)
- Testing
- KZR-616
- Where
- 36 sites in United States, Australia and 6 more
- Volunteers
- 69 people
- Sponsor
- Kezar Life Sciences, Inc.
Systemic Lupus Erythematosus
An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184
This is an adaptive, dose ranging, Phase II study to investigate the relationship between repeat doses of GSK2586184 and the pharmacodynamic effect and clinical efficacy in patients with active systemic lupus erythematosus (SLE).
- Trial name
- NCT01777256
- Testing
- GSK2586184 50 mg, GSK2586184 100 mg, GSK2586184 200 mg
- Where
- 53 sites in Argentina, Chile and 14 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Biomarker, Lipid
Shotgun Mass Spectrometry-based Lipid Profiling in Chronic Inflammatory Diseases
Collect blood from patients admitted for coronary angiography to tubes with heparin, centrifuge and collect plasma. This will be frozen at -80C.
- Conditions
- Biomarker, Lipid, Inflammation, Cardiovascular Diseases
- Trial name
- NCT04786431
- Testing
- Blood collection for lipid profiling by LC-MS
- Volunteers
- 427 people
- Sponsor
- Universidade Nova de Lisboa
Systemic Lupus Erythematosus
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
TQB3702 is a selective kinase inhibitor. This is a Phase II clinical study aimed at evaluating the efficacy and safety of TQB3702 tablets in patients with systemic lupus erythematosus.
- Trial name
- NCT06859931
- Testing
- TQB3702 Tablets
- Where
- 37 sites in China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Helicobacter Pylori Infection
H-pylori Infection With Disease Activity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
To find the relation of Helicobacter pylori with disease activity in SLE and RA
- Trial name
- NCT06586567
- Testing
- Full history , clinical examination, assesment of disease activity ,Laboratory investigations ( CBC , ESR, CRP Serum creatinine and blood urea, Random plas
- Volunteers
- 150 people
- Sponsor
- Assiut University
Lupus Nephritis (LN), ANCA-Associated Glomerulonephritis
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.
- Trial name
- MSC303 (NCT07000292)
- Testing
- Injection of MSC303
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Changzheng Hospital
System; Lupus Erythematosus
Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety of mesenchymal stromal cells (MSCs) obtained from umbilical cords for the treatment of adults with active systemic lupus erythematosus (SLE).
- Trial name
- NCT03171194
- Testing
- Low Dose Mesenchymal Stem Cells (MSCs)
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Medical University of South Carolina
Autoimmune Disease, Crohn Disease
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases.
- Conditions
- Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis
- Trial name
- NCT02925351
- Testing
- Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Systemic Lupus Erythematosus, SLE
JBT-101 in Systemic Lupus Erythematosus (SLE)
The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE).
- Conditions
- Systemic Lupus Erythematosus, SLE, Lupus
- Trial name
- NCT03093402
- Testing
- JBT-101
- Where
- 16 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus (SLE), Children
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
The goal of this clinical trial is to learn if blinatumomab works to treat refractory or active systemic lupus erythematosus (SLE) in children and adults. It will also learn about the safety of blinatumomab.
- Conditions
- Systemic Lupus Erythematosus (SLE), Children, Blinatumomab
- Trial name
- BRASLE (NCT06789107)
- Testing
- Blinatumomab 9ug
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Mao Jianhua
Systemic Lupus Erythematosus
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
Accelerated atherosclerosis is an established complication of systemic autoimmune diseases, particularly SLE. Young female patients with SLE are more likely to develop myocardial infarction than matched healthy controls, and CVD…
- Trial name
- ISLE (NCT04276701)
- Testing
- blood sample, Ultrasonography assessment, questionnaires
- Where
- 6 sites in France, Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital, Bordeaux
Transplantation, Systemic Lupus Erythematosus
Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.
PRIMAVERA is a Phase IIa clinical trial, with the objective to assess the immunologic response to HPV vaccine in a population of immunocompromised girls.
- Conditions
- Transplantation, Systemic Lupus Erythematosus, Systemic Immune Disease
- Trial name
- PRIMAVERA (NCT01687192)
- Testing
- HPV prophylactic vaccine Gardasil
- Where
- 9 sites in France
- Volunteers
- 37 people
- Sponsor
- University Hospital, Bordeaux
Lupus
Cardiac Imaging in Systemic Disorders: the ORACLES Registry
Autoimmune diseases affect a total of 5 to 10% of the population. These diseases are associated with an increased risk of developing cardiovascular pathologies.
- Trial name
- ORACLES (NCT07134166)
- Testing
- data collection
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.